SPECIAL ORDER ONLY!
20ml/10 dose and 50ml/25 dose and 100ml/50 dose are
TSV-2 Bovine Rhinotracheitis, Parainfluenza 3 Vaccine
TSV-2 is for vaccination of healthy cattle, including pregnant cows, as an aid in preventing infectious bovine rhinotracheitis caused by infectious bovine rhinotracheitis (IBR) virus and disease caused by PI3 (parainfluenza3) virus. The vaccine is prepared by growing attenuated virus strains on a bovine cell line. The virus fractions are combined and stabilized by freeze-drying. A sterile diluent is supplied for rehydration. TSV-2 is unique in that the virus strains it contains are temperature specific. Tests have shown that they will not grow in vivo at or above 39°C, the normal bovine body temperature. This restricts viral replication to the nasal mucosa, which is constantly ventilated and maintained at temperatures less than 39°C, even in the febrile animal. At this localized site, the temperature-specific viruses replicate and stimulate local and systemic immunity. Because the temperature-specific strains cannot grow in the internal body organs or developing fetus, pregnant cows may be safely vaccinated.
Aids in the prevention of diseases caused by infectious bovine rhinotracheitis (IBR) virus and disease caused by PI3 (parainfluenza3) virus.
•Intranasal (IN) administration results in rapid local immunity at the site of natural infection.
•Stimulates local and systemic immunity.
•Rapid onset of protection makes TSV-2 a quick-response tool in the face of a potential IBR outbreak in young cattle or when receiving long-haul, high-risk calves.
•Safe for use in pregnant cows.
•Single IN dose is 2mL, with annual revaccination.
Safety and Efficacy
Safety of the temperature-specific IBR strain was demonstrated in a test where it was administered to 1,019 pregnant cows in 12 herds. No abortions attributed to IBR were observed. In a controlled challenge-of-immunity test, five of five susceptible vaccinates were protected from a virulent IBR challenge that clinically affected all five nonvaccinated control calves. In a second challenge-of-immunity test, all 25 vaccinated calves were protected from a virulent PI3 challenge that produced clinical signs or temperature increase in six of seven nonvaccinated control calves. In an onset-of-protection study, two pairs of susceptible calves remained clinically normal when subjected to contact challenge 72 and 48 hours after vaccination with virulent IBR virus. One calf challenged 24 hours postvaccination remained normal, another exhibited mild clinical signs. All control calves and calves used for contact challenge were clinically affected.
Dosing & Administration
1.Store at 2°–7°C. Prolonged exposure to higher temperatures and/or direct sunlight may adversely affect potency. Do not freeze.
2.Use entire contents when first opened.
3.Sterilized syringes and needles should be used to administer this vaccine. Do not sterilize with chemicals because traces of disinfectant may inactivate the vaccine.
4.Burn containers and all unused contents.
5.Do not vaccinate within 21 days before slaughter.
6.Contains gentamicin as preservative.
7.As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy.
8.This product has been shown to be efficacious in healthy animals. A protective immune response may not be elicited if animals are incubating an infectious disease, are malnourished or parasitized, are stressed due to shipment or environmental conditions, are otherwise immunocompromised, or the vaccine is not administered in accordance with label directions.